RedHill Biopharma and IntelGenx Submit New Drug Application to FDA for RIZAPORTÂ for Migraines

RIZAPORTÂÂis a proprietary oral thinfilm formulation of rizatriptan for the treatment of acute migraines A Prescription Drug User Fee Act PDUFA date is expected to be set by the FDA for the first half of 2018 if the submission is deemed complete and ...